Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer

The primary outcome is monitor for toxicity effect for the combination therapy.

Inclusion criteria

• Patients with inoperable pancreatic cancer (ICD-10 C25.0-3) at the Department of Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to participate

Exclusion criteria

• Patient participated in an investigational study within 30 days prior to study entry (or, if longer, within five half-lives of the last dose of any investigational drug).
• Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.
• Patient has a history of cardiovascular ischemia, acute myocardial infarction or unstable angina within 3 months prior to study entry.
• Patient has a history of any psychiatric disorder or cognitive impairment that would interfere with participation in the study.
• Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.
• Patient requires dialysis or has severely impaired renal function, defined as a serum creatinine > 180 mmol/L at the Screening Visit.
• Patient has severe impairment of liver function, defined as a serum albumin level ≤ 25 g/L and/or a Protrombin Time INR > 2.3 (or APTT > 6 seconds above the upper limit of normal) at the Screening Visit.
• Patient is pregnant or is breast-feeding.
• Patient is allergic to or intolerant of gemcitabine
• Patient is allergic to or intolerant of SonoVue® BRACCO ultrasound contrast agent
• Any reason why, in the opinion of the investigator, the patient should not participate.